Thymosin: basic properties and clinical application in the treatment of immunodeficiency diseases and cancer.
Thymosin fraction 5 contains a family of polypeptides with varying biological activities. Current efforts in the thymosin research program are involved in further chemical characterization of thymosin peptides and evaluation of clinical immunotherapeutic protocols. Recent clinical studies with thymosin fraction 5 have shown therapeutic potentials for treatment of patients with primary immunodeficiency diseases and cancer.
D006152:Cyclic GMP / Q000032:analysis; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D013947:Thymosin / Q000032:analysis / Q000494:pharmacology / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*
D013951:Thymus Hormones; D013947:Thymosin; D006152:Cyclic GMP